Cryoport, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2019
January 09, 2020 at 04:55 pm EST
Share
Cryoport, Inc. provided earnings guidance for the fourth quarter and full year ended December 31, 2019. The company announced preliminary revenue for the twelve and three-month periods ended December 31, 2019, based upon preliminary unaudited financial information. Subject to quarter-end closing adjustments, the Company expects to report revenue of approximately $33.9 million and $9.2 million for the twelve and three-month periods ended December 31, 2019, an increase of 73% compared to $19.6 million and 61% compared to $5.7 million for the twelve and three-month periods ended December 31, 2018, respectively.
Cryoport, Inc. is engaged in supply chain solutions for cell and gene therapies. The Companyâs supply chain solutions enable manufacturers, contract manufacturers (CDMOâs), contract research organizations (CROâs), developers, and researchers to carry out their business with certainty. The Company provides a broad array of supply chain solutions for the life sciences industry. Through its platform of critical products and solutions, including advanced temperature-controlled packaging, informatics, specialized bio-logistics services, bio-storage, bio-services, and cryogenic systems, the Company is enabling the future of medicine worldwide, through its systems, compliant procedures, and approach to supply chain management. Its products and services include Cryoport Express Shippers, Cryoport ELITE Shipper Systems, Cryoport Consulting Services, Cryoport Bioservices, CRYOGENE, CRYOPDP Temperature-controlled Logistics, Cryoport Cryoshuttle, IntegriCell Services, Tec4Med, and others.